Search
Search
About
Log in
Join
Experiences with
Combination therapy
Posts
Communities
16,124 public posts
Filter results
Should the dose of Dutasteride be increased?
[u]
THERAPY
: Dutasteride + ADT [/u] Another interesting question is what would happen if you combined traditional ADT with Dutasteride? I think the combo would be fantastic! The main goal should be to reduce DHT as low as possible.
[u]
THERAPY
: Dutasteride + ADT [/u] Another interesting question is what would happen if you combined traditional ADT with Dutasteride? I think the combo would be fantastic! The main goal should be to reduce DHT as low as possible.
janebob99
in
Advanced Prostate Cancer
2 months ago
Should the dose of Dutasteride be increased?
[u]
THERAPY
: Dutasteride + ADT [/u] Another interesting question is what would happen if you combined traditional ADT with Dutasteride? I think the combo would be fantastic! The main goal should be to reduce DHT as low as possible.
[u]
THERAPY
: Dutasteride + ADT [/u] Another interesting question is what would happen if you combined traditional ADT with Dutasteride? I think the combo would be fantastic! The main goal should be to reduce DHT as low as possible.
janebob99
in
Prostate Cancer Network
2 months ago
Rux and IFN combo therapy
https://ashpublications.org/blood/article/140/Supplement%201/6806/492684/
Combination
-
Therapy
-with-Ruxolitinib-and --
https://ashpublications.org/blood/article/140/Supplement%201/6806/492684/
Combination
-
Therapy
-with-Ruxolitinib-and --
EPguy
in
MPN Voice
1 year ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Thyroid treatment for new patients in U.S.
In 2021, the ATA, along with European and British thyroid societies, issued a consensus statement noting that new trials of triiodothyronine (T3)/T4
combination
therapy
were "justified."
In 2021, the ATA, along with European and British thyroid societies, issued a consensus statement noting that new trials of triiodothyronine (T3)/T4
combination
therapy
were "justified."
WiscGuy
in
Thyroid UK
10 months ago
Transformation of Richter's Transformation Treatment to combination targeted therapy - tislelizumab +zanubrutinib (ASH 2023)
Richter's Transformation treatments are typically fixed term R-CHOP*, or modifications of that chemoimmunity therapy. So it's encouraging to hear that [i]"In a phase 2 trial, anti-PD-1 inibitor tislelizumab + next gen BTK inhibitor zanubrutinib had an overall response rate of 58.3% in patients with Richter's
Richter's Transformation treatments are typically fixed term R-CHOP*, or modifications of that chemoimmunity therapy. So it's encouraging to hear that [i]"In a phase 2 trial, anti-PD-1 inibitor tislelizumab + next gen BTK inhibitor zanubrutinib had an overall response rate of 58.3% in patients with Richter's
AussieNeil
Administrator
in
CLL Support
5 months ago
PCNA gene attack -- for solid tumors
Pasted from a publicly avaiilable website A "holy grail" molecule that kills all solid cancer tumors, leaving other cells unaffected, has been developed by scientists. The team at the City of Hope, one of the largest cancer research and treatment organizations in the United States, made the breakthrough
Pasted from a publicly avaiilable website A "holy grail" molecule that kills all solid cancer tumors, leaving other cells unaffected, has been developed by scientists. The team at the City of Hope, one of the largest cancer research and treatment organizations in the United States, made the breakthrough
Derf4223
in
Advanced Prostate Cancer
9 months ago
XTANDI(Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
therapy
Approval is based on results from the positive Phase 3 EMBARK study which showed XTANDI alone or in combination with leuprolide reduced the risk of metastasis or death
therapy
Approval is based on results from the positive Phase 3 EMBARK study which showed XTANDI alone or in combination with leuprolide reduced the risk of metastasis or death
Maxone73
in
Advanced Prostate Cancer
7 days ago
BTK Inhibitor Therapy for CLL: An International Perspective - Stephan Stilgenbauer, MD
-
Combination
Therapy
In addition to continuous BTK inhibitor monotherapy, another first-line
therapy
option for CLL is
combination
therapy
with venetoclax plus obinutuzumab, an anti-CD20 antibody.
-
Combination
Therapy
In addition to continuous BTK inhibitor monotherapy, another first-line
therapy
option for CLL is
combination
therapy
with venetoclax plus obinutuzumab, an anti-CD20 antibody.
lankisterguy
Volunteer
in
CLL Support
1 year ago
German doctors' prescribing T4 or combination therapy
Of responding members, 98.6% used levothyroxine (LT4) as the treatment of choice, and 45.4% also prescribed
combination
therapy
with liothyronine (LT4+LT3) in their clinical practice (p<0.001).
Of responding members, 98.6% used levothyroxine (LT4) as the treatment of choice, and 45.4% also prescribed
combination
therapy
with liothyronine (LT4+LT3) in their clinical practice (p<0.001).
diogenes
in
Thyroid UK
1 year ago
Hashimotos double vision
I will now try to arrange to see a private endocrinologist and attempt to get a prescription for T3/
combination
therapy
. My optician thinks the double vision might stop when I am properly medicated. Anyway just wondered about the double vision thing.
I will now try to arrange to see a private endocrinologist and attempt to get a prescription for T3/
combination
therapy
. My optician thinks the double vision might stop when I am properly medicated. Anyway just wondered about the double vision thing.
Girtonian
in
Thyroid UK
1 year ago
Delta Gold & Docetaxel
"
Combination
therapy
is one tool used to overcome therapeutic resistance and drug toxicity. Evaluating the combined effect of δ-TT and docetaxel (DTX), we found that δ-TT potentiates DTX cytotoxicity in DU145 cells.
"
Combination
therapy
is one tool used to overcome therapeutic resistance and drug toxicity. Evaluating the combined effect of δ-TT and docetaxel (DTX), we found that δ-TT potentiates DTX cytotoxicity in DU145 cells.
pjoshea13
in
Fight Prostate Cancer
1 year ago
PSA rising on Triplet Therapy after <18m
Hi all. Hope you are keeping your spirits high. This is a follow up to a post I made in 2022 about my father. I haven't posted since, which reflects the period of relative normalcy that followed the commencement of ADT (triplet therapy) at MSK. I want to pause to appreciate that since I know most of
Hi all. Hope you are keeping your spirits high. This is a follow up to a post I made in 2022 about my father. I haven't posted since, which reflects the period of relative normalcy that followed the commencement of ADT (triplet therapy) at MSK. I want to pause to appreciate that since I know most of
nyc_son
in
Advanced Prostate Cancer
2 months ago
Results on triple combination (A+V+O) for high risk patients -with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-cll
The Bottom Line: In this ongoing trial, the triple
combination
therapy
using acalabrutinib, venetoclax, and obinutuzumab is highly active.
The Bottom Line: In this ongoing trial, the triple
combination
therapy
using acalabrutinib, venetoclax, and obinutuzumab is highly active.
spi3
in
CLL Support
1 year ago
Private Blood Test Results
Hello, Diagnosed with Hashimoto’s 2019, it was a long and sickly road to diagnosis and treatment. Levothyroxine only didn’t work for me and after a couple of not so great endo appointments I finally found a really good endocrinologist who agreed to add in liothyronine and commenced me on 20mcg
Hello, Diagnosed with Hashimoto’s 2019, it was a long and sickly road to diagnosis and treatment. Levothyroxine only didn’t work for me and after a couple of not so great endo appointments I finally found a really good endocrinologist who agreed to add in liothyronine and commenced me on 20mcg
Lassithi
in
Thyroid UK
3 months ago
Relapsed CLL: New Approaches Prolong Survival
In people who are genomically unstable, almost half will have their CLL progress on single agent BTK inhibitor
therapy
. These patients, I'd like to treat with
combination
of a Bruton's tyrosine kinase inhibitor plus venetoclax," said Richard R.
In people who are genomically unstable, almost half will have their CLL progress on single agent BTK inhibitor
therapy
. These patients, I'd like to treat with
combination
of a Bruton's tyrosine kinase inhibitor plus venetoclax," said Richard R.
Jm954
Administrator
in
CLL Support
1 year ago
The T3-4-Hypo trial
[i][/i] [i]
The T3-4-Hypo trial
[/i] [i]A Dutch national randomized placebo-controlled double-blind multicenter trial of LT4/LT3
combination
therapy
in patients with autoimmune hypothyroidism.
[i][/i] [i]
The T3-4-Hypo trial
[/i] [i]A Dutch national randomized placebo-controlled double-blind multicenter trial of LT4/LT3
combination
therapy
in patients with autoimmune hypothyroidism.
helvella
Thyroid UK
in
Thyroid UK
1 year ago
Update 7.5
I am interested in the potential of
combination
therapy
but would prefer mono-therapy with Besremi providing I tolerate a higher dose. We will see how things go. So, things are going well. I remain very pleased with my response to Besremi.
I am interested in the potential of
combination
therapy
but would prefer mono-therapy with Besremi providing I tolerate a higher dose. We will see how things go. So, things are going well. I remain very pleased with my response to Besremi.
hunter5582
in
MPN Voice
1 year ago
The T3-4-Hypo trial (Netherlands)
[i]
The T3-4-Hypo trial
[/i] [i]A Dutch national randomized placebo-controlled double-blind multicenter trial of LT4/LT3
combination
therapy
in patients with autoimmune hypothyroidism.
[i]
The T3-4-Hypo trial
[/i] [i]A Dutch national randomized placebo-controlled double-blind multicenter trial of LT4/LT3
combination
therapy
in patients with autoimmune hypothyroidism.
helvella
Thyroid UK
in
Thyroid UK
1 year ago
Poor converters
Can anyone give me some stats on the percentage of patients in the UK needing combined therapy T4/T3? That is, percentage of poor converters? Percentage of faulty genes Di01 and DI02? Am writing a follow-up article to the one published for Central Bylines https://centralbylines.co.uk/big-pharma-the-nhs-thyroid-disease-and-me
Can anyone give me some stats on the percentage of patients in the UK needing combined therapy T4/T3? That is, percentage of poor converters? Percentage of faulty genes Di01 and DI02? Am writing a follow-up article to the one published for Central Bylines https://centralbylines.co.uk/big-pharma-the-nhs-thyroid-disease-and-me
judycopage
in
Thyroid UK
11 months ago
Shingrix vaccine for immunosuppressed people aged 50+
I thought I would just post this from the gov.uk website because I have just a bit of struggle convincing our surgery that I was eligible, so maybe other people haven't been invited either. The full list is on chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://assets.publishing.service.gov.uk
I thought I would just post this from the gov.uk website because I have just a bit of struggle convincing our surgery that I was eligible, so maybe other people haven't been invited either. The full list is on chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://assets.publishing.service.gov.uk
Sharitone
in
PMRGCAuk
6 months ago
1
...
3
4
5
...
100
Next page
10
20
30
40
50
60
70
80
90
100
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
4335 results
Thyroid UK
2365 results
Endometriosis UK
1837 results
View top 10 communities
Sort by
Most Relevant
Newest